Drug (trial) | Class (comparator) | Primary outcomes vs comparator (hazard ratio [HR]) | 95% CIs | P value |
---|---|---|---|---|
Abiraterone acetate + prednisone (COU-AA-301) | Antiandrogen (prednisone/placebo) | Median OS = 14.8 vs 10.9 mo (HR = 0.65) | 0.54-0.77 | < 0.0001 |
 |  | Median TTPP = 10.2 vs 6.6 mo (HR = 0.58) | 0.46-0.73 | < 0.0001 |
 |  | Median rPFS = 5.6 vs 3.6 mo (HR = 0.67) | 0.58-0.78 | < 0.0001 |
 |  | PSA response: 38% vs 10% | - | < 0.0001 |
Cabazitaxel + prednisone (TROPIC) | Chemotherapy (mitoxantrone/pred-nisone) | Median OS = 15.1 vs 12.7 mo (HR = 0.70) | 0.59-0.83 | < 0.0001 |
 |  | Median PFS = 2.8 vs 1.4 mo (HR = 0.74) | 0.64-0.86 | < 0.0001 |
 |  | Tumor response = 14.4% vs 4.4% | - | 0.0005 |
 |  | PSA response = 39.2% vs 17.8% | - | 0.0002 |